Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax COIN Option Income Strategy ETF (CONY) vs Novavax Inc (NVAX) Price & Performance

YieldMax COIN Option Income Strategy ETFTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

YieldMax COIN Option Income Strategy ETF vs Novavax Inc — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $19.88, while Novavax Inc trades at $8.48 (market cap $1.38B). The key difference: Novavax Inc is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.

CONYNVAX
Sector
Income / Options OverlayHealth
52-Week High
$103.20$11.19
52-Week Low
$18.43$6.22
Market Cap
$1.38B
Enterprise Value
$889.29M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax COIN Option Income Strategy ETF

CONY trades at $19.46, down 0.87% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF has paid consistent weekly dividends, with recent payouts ranging from $0.24 to $0.56 per share. Key support lies at $19, with resistance at $20. Recent news highlights YieldMax's weekly distribution announcements, but some articles express concern over the ETF's long-term performance despite its high yield.

The outlook for CONY hinges on its ability to sustain high distributions through options strategies on Coinbase stock. Risks include the underlying volatility of Coinbase and the potential for distribution cuts if option income declines. Investors should weigh the attractive yield against the fund's bearish price trend and dependence on a single stock's options market.

Novavax Inc

Novavax (NVAX) trades at $8.91, down 4.5% today, with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with strong revenue of $1.12B in 2025 but negative equity of -$623.84M. Analyst consensus remains bullish with a $14.00 price target, though cash flow trends show ongoing operational losses. Recent news highlights shareholder dissent and market underperformance compared to peers.

The outlook is cautious; while valuation ratios like P/E of 3.14 appear attractive, persistent negative cash flow and high liabilities pose significant risks. Upside depends on sustainable profitability and execution amid competitive vaccine markets. Investors should weigh analyst optimism against fundamental weaknesses and volatility.

Returns comparison

Trailing returns across standard periods

About YieldMax COIN Option Income Strategy ETF

CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.

Read more on CONY

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX